JP2015535289A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015535289A5 JP2015535289A5 JP2015540796A JP2015540796A JP2015535289A5 JP 2015535289 A5 JP2015535289 A5 JP 2015535289A5 JP 2015540796 A JP2015540796 A JP 2015540796A JP 2015540796 A JP2015540796 A JP 2015540796A JP 2015535289 A5 JP2015535289 A5 JP 2015535289A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- following formulation
- tablet
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- PURKAOJPTOLRMP-UHFFFAOYSA-N CC(C)(C)c(cc(C(C)(C)C)c(O)c1)c1NC(C1=CNc2ccccc2C1=O)=O Chemical compound CC(C)(C)c(cc(C(C)(C)C)c(O)c1)c1NC(C1=CNc2ccccc2C1=O)=O PURKAOJPTOLRMP-UHFFFAOYSA-N 0.000 description 1
Applications Claiming Priority (11)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261721622P | 2012-11-02 | 2012-11-02 | |
| US61/721,622 | 2012-11-02 | ||
| US201261728328P | 2012-11-20 | 2012-11-20 | |
| US61/728,328 | 2012-11-20 | ||
| US201361770668P | 2013-02-28 | 2013-02-28 | |
| US61/770,668 | 2013-02-28 | ||
| US201361824005P | 2013-05-16 | 2013-05-16 | |
| US61/824,005 | 2013-05-16 | ||
| US201361840668P | 2013-06-28 | 2013-06-28 | |
| US61/840,668 | 2013-06-28 | ||
| PCT/US2013/067952 WO2014071122A1 (en) | 2012-11-02 | 2013-11-01 | Pharmaceutical compositions for the treatment of cftr mediated diseases |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018038741A Division JP2018090626A (ja) | 2012-11-02 | 2018-03-05 | Ｃｆｔｒが媒介する疾患の処置のための医薬組成物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015535289A JP2015535289A (ja) | 2015-12-10 |
| JP2015535289A5 true JP2015535289A5 (enExample) | 2016-12-15 |
| JP6302923B2 JP6302923B2 (ja) | 2018-03-28 |
Family
ID=50628072
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015540796A Active JP6302923B2 (ja) | 2012-11-02 | 2013-11-01 | Ｃｆｔｒが媒介する疾患の処置のための医薬組成物 |
| JP2018038741A Withdrawn JP2018090626A (ja) | 2012-11-02 | 2018-03-05 | Ｃｆｔｒが媒介する疾患の処置のための医薬組成物 |
| JP2019087813A Active JP7003085B2 (ja) | 2012-11-02 | 2019-05-07 | Ｃｆｔｒが媒介する疾患の処置のための医薬組成物 |
| JP2021214209A Pending JP2022034069A (ja) | 2012-11-02 | 2021-12-28 | Ｃｆｔｒが媒介する疾患の処置のための医薬組成物 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018038741A Withdrawn JP2018090626A (ja) | 2012-11-02 | 2018-03-05 | Ｃｆｔｒが媒介する疾患の処置のための医薬組成物 |
| JP2019087813A Active JP7003085B2 (ja) | 2012-11-02 | 2019-05-07 | Ｃｆｔｒが媒介する疾患の処置のための医薬組成物 |
| JP2021214209A Pending JP2022034069A (ja) | 2012-11-02 | 2021-12-28 | Ｃｆｔｒが媒介する疾患の処置のための医薬組成物 |
Country Status (30)
| Country | Link |
|---|---|
| US (4) | US20140163068A1 (enExample) |
| EP (3) | EP4556008A3 (enExample) |
| JP (4) | JP6302923B2 (enExample) |
| KR (1) | KR102396897B1 (enExample) |
| CN (2) | CN111671751A (enExample) |
| AR (1) | AR093340A1 (enExample) |
| AU (4) | AU2013337730B2 (enExample) |
| BR (1) | BR112015009913B1 (enExample) |
| CA (1) | CA2890106C (enExample) |
| CL (1) | CL2015001148A1 (enExample) |
| CY (1) | CY1121070T1 (enExample) |
| DK (2) | DK2914248T4 (enExample) |
| ES (2) | ES3009747T3 (enExample) |
| FI (2) | FI2914248T4 (enExample) |
| HR (2) | HRP20181740T4 (enExample) |
| HU (2) | HUE070382T2 (enExample) |
| IL (2) | IL283276B2 (enExample) |
| LT (2) | LT3470063T (enExample) |
| MX (2) | MX368353B (enExample) |
| NZ (2) | NZ708474A (enExample) |
| PL (2) | PL3470063T3 (enExample) |
| PT (2) | PT2914248T (enExample) |
| RS (2) | RS57831B2 (enExample) |
| SG (3) | SG10201913581UA (enExample) |
| SI (2) | SI3470063T1 (enExample) |
| SM (2) | SMT201800590T1 (enExample) |
| TR (1) | TR201815218T4 (enExample) |
| TW (2) | TW201422253A (enExample) |
| UA (2) | UA117464C2 (enExample) |
| WO (1) | WO2014071122A1 (enExample) |
Families Citing this family (97)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7973169B2 (en) | 2003-09-06 | 2011-07-05 | Vertex Pharmaceuticals Incorporated | Modulators of ATP-Binding Cassette transporters |
| US7977322B2 (en) | 2004-08-20 | 2011-07-12 | Vertex Pharmaceuticals Incorporated | Modulators of ATP-binding cassette transporters |
| PL2502911T3 (pl) | 2004-06-24 | 2017-09-29 | Vertex Pharma | Modulatory transporterów kasety wiążącej ATP |
| CA2618057A1 (en) | 2005-08-11 | 2007-02-22 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator |
| DK1945632T3 (da) | 2005-11-08 | 2013-12-16 | Vertex Pharma | Heterocycliske modulatorer af ATP-bindende kassettetransportører |
| WO2007079139A2 (en) | 2005-12-28 | 2007-07-12 | Vertex Pharmaceuticals, Inc. | Solid forms of n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide |
| US7645789B2 (en) | 2006-04-07 | 2010-01-12 | Vertex Pharmaceuticals Incorporated | Indole derivatives as CFTR modulators |
| USRE50453E1 (en) | 2006-04-07 | 2025-06-10 | Vertex Pharmaceuticals Incorporated | Indole derivatives as CFTR modulators |
| US10022352B2 (en) | 2006-04-07 | 2018-07-17 | Vertex Pharmaceuticals Incorporated | Modulators of ATP-binding cassette transporters |
| DK2007756T3 (en) | 2006-04-07 | 2015-10-05 | Vertex Pharma | MODULATORS OF ATP BINDING CASSETTE TRANSPORT |
| US8563573B2 (en) | 2007-11-02 | 2013-10-22 | Vertex Pharmaceuticals Incorporated | Azaindole derivatives as CFTR modulators |
| EP2789606B1 (en) | 2007-05-09 | 2017-11-15 | Vertex Pharmaceuticals Incorporated | Modulators of CFTR |
| JP5389030B2 (ja) | 2007-08-24 | 2014-01-15 | バーテックス ファーマシューティカルズ インコーポレイテッド | （特に）嚢胞性線維症の処置に有用なイソチアゾロピリジノン |
| PL2578571T3 (pl) | 2007-11-16 | 2016-03-31 | Vertex Pharma | Modulatory izochinolinowe transporterów zawierających kasetę wiążącą ATP |
| ES2604555T3 (es) | 2007-12-07 | 2017-03-07 | Vertex Pharmaceuticals Incorporated | Procedimiento para producir ácidos cicloalquilcarboxiamido-piridinabenzoicos |
| KR20160040745A (ko) | 2007-12-07 | 2016-04-14 | 버텍스 파마슈티칼스 인코포레이티드 | 3-(6-(1-(2,2-디플루오로벤조[ｄ][1,3]디옥솔-5-일)사이클로프로판카복스아미도)-3-메틸피리딘-2-일)벤조산의 고체 형태 |
| US20100036130A1 (en) | 2007-12-07 | 2010-02-11 | Vertex Pharmaceuticals Incorporated | Processes for producing cycloalkylcarboxamido-pyridine benzoic acids |
| NZ720282A (en) | 2008-02-28 | 2017-12-22 | Vertex Pharma | Heteroaryl derivatives as cftr modulators |
| US12458635B2 (en) | 2008-08-13 | 2025-11-04 | Vertex Pharmaceuticals Incorporated | Pharmaceutical composition and administrations thereof |
| US20100074949A1 (en) | 2008-08-13 | 2010-03-25 | William Rowe | Pharmaceutical composition and administration thereof |
| CA3071058C (en) | 2009-03-20 | 2023-01-24 | Vertex Pharmaceuticals Incorporated | Process for making modulators of cystic fibrosis transmembrane conductance regulator |
| US8802868B2 (en) | 2010-03-25 | 2014-08-12 | Vertex Pharmaceuticals Incorporated | Solid forms of (R)-1(2,2-difluorobenzo[D][1,3]dioxo1-5-yl)-N-(1-(2,3-dihydroxypropyl-6-fluoro-2-(1-hydroxy-2-methylpropan2-yl)-1H-Indol-5-yl)-Cyclopropanecarboxamide |
| NZ602838A (en) | 2010-04-07 | 2015-06-26 | Vertex Pharma | Pharmaceutical compositions of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid and administration thereof |
| CN102933206A (zh) | 2010-04-07 | 2013-02-13 | 弗特克斯药品有限公司 | 3-(6-(1-(2，2-二氟苯并[d][1，3]二氧杂环戊烯-5-基)环丙烷甲酰胺基)-3-甲基吡啶-2-基)苯甲酸的固体形式 |
| KR20130056244A (ko) | 2010-04-22 | 2013-05-29 | 버텍스 파마슈티칼스 인코포레이티드 | 시클로알킬카르복스아미도-인돌 화합물의 제조 방법 |
| HUE047354T2 (hu) | 2011-05-18 | 2020-04-28 | Vertex Pharmaceuticals Europe Ltd | Ivacaftor deuterizált származékai |
| KR101985044B1 (ko) | 2011-11-08 | 2019-05-31 | 버텍스 파마슈티칼스 인코포레이티드 | Atp-결합 카세트 수송체의 조절제 |
| AU2013207252B2 (en) | 2012-01-06 | 2016-06-09 | H.Lundbeck A/S | Carbamate compounds and pharmaceutical compositions thereof |
| PT2806859T (pt) | 2012-01-25 | 2019-09-04 | Vertex Pharma | Formulações de ácido 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-il)ciclopropanocarboxamido)-3-metilpiridin-2-il)benzoico |
| MX389751B (es) | 2012-02-27 | 2025-03-20 | Vertex Pharma | Composición farmacéutica y administraciones de la misma. |
| AU2013290444B2 (en) | 2012-07-16 | 2018-04-26 | Vertex Pharmaceuticals Incorporated | Pharmaceutical compositions of (R)-1-(2,2-diflurorbenzo[d][1,3]dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl) cyclopropanecarboxamide and administration thereof |
| EP4556008A3 (en) * | 2012-11-02 | 2025-08-27 | Vertex Pharmaceuticals Incorporated | Pharmaceutical compositions for the treatment of cftr mediated diseases |
| US9303918B2 (en) * | 2013-03-15 | 2016-04-05 | Monosol Rx, Llc | Process for drying a wet film with control of loss on drying |
| US20160074374A1 (en) * | 2013-04-26 | 2016-03-17 | Vertex Pharmaceuticals Incorporated | Correctors acting through msd1 of cftr protein |
| WO2015073231A1 (en) * | 2013-11-12 | 2015-05-21 | Vertex Pharmaceuticals Incorporated | Process of preparing pharmaceutical compositions for the treatment of cftr mediated diseases |
| KR102447581B1 (ko) | 2014-04-15 | 2022-09-28 | 버텍스 파마슈티칼스 인코포레이티드 | 낭포성 섬유증 막전도 조절자 매개 질환 치료용 약제학적 조성물 |
| SG10201913603QA (en) | 2014-10-06 | 2020-02-27 | Vertex Pharma | Modulators of cystic fibrosis transmembrane conductance regulator |
| RU2749213C2 (ru) | 2014-10-07 | 2021-06-07 | Вертекс Фармасьютикалз Инкорпорейтед | Сокристаллы модуляторов регулятора трансмембранной проводимости при кистозном фиброзе |
| SG11201703963QA (en) | 2014-11-18 | 2017-06-29 | Vertex Pharma | Process of conducting high throughput testing high performance liquid chromatography |
| CA2984480A1 (en) | 2015-05-11 | 2016-11-17 | Abide Therapeutics, Inc. | Methods of treating inflammation or neuropathic pain |
| AU2016327603B2 (en) | 2015-09-25 | 2021-04-22 | Vertex Pharmaceuticals (Europe) Limited | Deuterated CFTR potentiators |
| WO2017151725A1 (en) * | 2016-03-03 | 2017-09-08 | Nivalis Therapeutics, Inc. | Formulations of an s-nitrosoglutathione reductase inhibitor |
| EP3436446B1 (en) | 2016-03-31 | 2023-06-07 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator |
| US10376501B2 (en) | 2016-04-25 | 2019-08-13 | Druggability Technologies Ip Holdco Limited | Complexes of lumacaftor and its salts and derivatives, process for the preparation thereof and pharmaceutical compositions containing them |
| HUP1600271A2 (hu) * | 2016-04-25 | 2017-10-30 | Druggability Tech Ip Holdco Ltd | Ivacaftor és Lumacaftor sóinak és származékainak komplexei, eljárás azok elõállítására és azok gyógyszerészetileg elfogadható készítményei |
| US10206915B2 (en) | 2016-04-25 | 2019-02-19 | Druggability Technologies Ip Holdco Limited | Complexes of Ivacaftor and its salts and derivatives, process for the preparation thereof and pharmaceutical compositions containing them |
| HUP1600270A2 (hu) | 2016-04-25 | 2017-10-30 | Druggability Tech Ip Holdco Ltd | Ivacaftornak, sóinak és származékainak komplexei, eljárás azok elõállítására és azok gyógyszerészetileg elfogadott készítményei |
| HUP1600269A2 (hu) | 2016-04-25 | 2017-10-30 | Druggability Tech Ip Holdco Ltd | Lumacaftornak, sóinak és származékainak komplexei, eljárás azok elõállítására és azok gyógyászati készítményei |
| US10383865B2 (en) | 2016-04-25 | 2019-08-20 | Druggability Technologies Ip Holdco Limited | Pharmaceutical combination composition comprising complex formulations of Ivacaftor and Lumacaftor and their salts and derivatives, process for their preparation thereof and pharmaceutical compositions containing them |
| US10570115B2 (en) | 2016-09-30 | 2020-02-25 | Vertex Pharmaceuticals Incorporated | Modulator of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator |
| CN110290791A (zh) * | 2016-11-16 | 2019-09-27 | 灵北拉荷亚研究中心公司 | 药物制剂 |
| ES2966939T3 (es) | 2016-11-16 | 2024-04-25 | H Lundbeck As | Una forma cristalina de un inhibidor de MAGL |
| HRP20201946T1 (hr) | 2016-12-09 | 2021-01-22 | Vertex Pharmaceuticals Incorporated | Modulator regulatora transmembranske provodljivosti cistične fibroze, farmaceutski sastavi, postupci liječenja, i postupak za dobivanje modulatora |
| MA54105A (fr) | 2017-06-08 | 2021-09-15 | Vertex Pharma | Méthodes de traitement de la fibrose kystique |
| US11517564B2 (en) | 2017-07-17 | 2022-12-06 | Vertex Pharmaceuticals Incorporated | Methods of treatment for cystic fibrosis |
| ES2912657T3 (es) | 2017-08-02 | 2022-05-26 | Vertex Pharma | Procesos para preparar compuestos de pirrolidina |
| WO2019079760A1 (en) | 2017-10-19 | 2019-04-25 | Vertex Pharmaceuticals Incorporated | CRYSTALLINE FORMS AND COMPOSITIONS OF CFTR MODULATORS |
| SG11202004264VA (en) | 2017-12-01 | 2020-06-29 | Vertex Pharma | Processes for making modulators of cystic fibrosis transmembrane conductance regulator |
| MA51039A (fr) | 2017-12-08 | 2020-10-14 | Vertex Pharma | Procédés pour préparer des modulateurs du régulateur de la conductance transmembranaire de la mucoviscidose |
| TWI810243B (zh) | 2018-02-05 | 2023-08-01 | 美商維泰克斯製藥公司 | 用於治療囊腫纖化症之醫藥組合物 |
| MD3752510T2 (ro) | 2018-02-15 | 2023-06-30 | Vertex Pharma | Macrociclii ca modulatori ai regulatorului conductanței transmembranare în fibroza chistică, compoziții farmaceutice ale acestora, utilizarea lor în tratamentul fibrozei chistice, și procedeu pentru fabricarea acestora |
| US20210139514A1 (en) | 2018-04-05 | 2021-05-13 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator |
| EP3774825A1 (en) | 2018-04-13 | 2021-02-17 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator |
| BR112021009145A2 (pt) | 2018-11-14 | 2021-08-10 | Vertex Pharmaceuticals Incorporated | métodos de tratamento para fibrose cística |
| AR118555A1 (es) | 2019-04-03 | 2021-10-20 | Vertex Pharma | Agentes moduladores del regulador de la conductancia transmembrana de la fibrosis quística |
| WO2020214921A1 (en) | 2019-04-17 | 2020-10-22 | Vertex Pharmaceuticals Incorporated | Solid forms of modulators of cftr |
| TWI899097B (zh) | 2019-08-14 | 2025-10-01 | 美商維泰克斯製藥公司 | 製備cftr調節劑之方法 |
| CA3150162A1 (en) | 2019-08-14 | 2021-02-18 | Vertex Pharmaceuticals Incorporated | Crystalline forms of cftr modulators |
| NZ785044A (en) | 2019-08-14 | 2025-10-31 | Vertex Pharma | Modulators of cystic fibrosis transmembrane conductance regulator |
| TWI867024B (zh) | 2019-08-14 | 2024-12-21 | 美商維泰克斯製藥公司 | 囊腫纖維化跨膜傳導調節蛋白之調節劑 |
| US11904006B2 (en) | 2019-12-11 | 2024-02-20 | University Of Iowa Research Foundation | Poly(diaminosulfide) particle-based vaccine |
| IL297470A (en) | 2020-04-21 | 2022-12-01 | H Lundbeck As | Synthesis of a monoacylglycerol lipase inhibitor |
| WO2022194399A1 (en) | 2020-07-13 | 2022-09-22 | Idorsia Pharmaceuticals Ltd | Macrocycles as cftr modulators |
| CR20230120A (es) | 2020-08-07 | 2023-09-01 | Vertex Pharma | Moduladores del regulador de la conductancia transmembrana de la fibrosis quística |
| WO2022076628A1 (en) | 2020-10-07 | 2022-04-14 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator |
| EP4225446A1 (en) | 2020-10-07 | 2023-08-16 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator |
| WO2022076626A1 (en) | 2020-10-07 | 2022-04-14 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator |
| WO2022076629A1 (en) | 2020-10-07 | 2022-04-14 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator |
| EP4225761A1 (en) | 2020-10-07 | 2023-08-16 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator |
| US20230365587A1 (en) | 2020-10-07 | 2023-11-16 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator |
| BR112023006381A2 (pt) | 2020-10-07 | 2023-09-26 | Vertex Pharma | Moduladores de regulador de condutância transmembrana de fibrose cística |
| EP4225748A1 (en) | 2020-10-07 | 2023-08-16 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator |
| KR20230104619A (ko) | 2020-10-07 | 2023-07-10 | 버텍스 파마슈티칼스 인코포레이티드 | 낭성 섬유증 막관통 전도도 조절자의 조절제 |
| KR20230107725A (ko) | 2020-10-07 | 2023-07-17 | 버텍스 파마슈티칼스 인코포레이티드 | 낭성 섬유증 막관통 전도도 조절자의 조절제 |
| US12324802B2 (en) | 2020-11-18 | 2025-06-10 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator |
| KR20230118123A (ko) | 2020-12-10 | 2023-08-10 | 버텍스 파마슈티칼스 인코포레이티드 | 낭성 섬유증 치료 방법 |
| US20240100183A1 (en) * | 2020-12-11 | 2024-03-28 | University Of Iowa Research Foundation | Compositions comprising molecules for cystic fibrosis treatment |
| EP4304593A4 (en) * | 2021-03-09 | 2024-08-07 | Laurus Labs Limited | ORAL FILM OF CFTR MODULATOR(S) |
| KR20240144973A (ko) | 2022-02-03 | 2024-10-04 | 버텍스 파마슈티칼스 인코포레이티드 | 낭성 섬유증 치료 방법 |
| AU2023218262A1 (en) | 2022-02-08 | 2024-08-22 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator |
| KR20250008540A (ko) | 2022-04-06 | 2025-01-14 | 버텍스 파마슈티칼스 인코포레이티드 | 낭성 섬유증 막관통 전도도 조절자의 조절제 |
| CN119947720A (zh) | 2022-05-16 | 2025-05-06 | 弗特克斯药品有限公司 | 治疗囊性纤维化的方法 |
| CN119894906A (zh) | 2022-09-15 | 2025-04-25 | 爱杜西亚药品有限公司 | 大环cftr调节剂 |
| CA3267788A1 (en) | 2022-09-15 | 2024-03-21 | Idorsia Pharmaceuticals Ltd | COMBINATION OF MACROCYCLIC CFTR MODULATORS WITH CFTR CORRECTORS AND/OR CFTR POTENTIALIZERS |
| KR20250065909A (ko) | 2022-09-15 | 2025-05-13 | 이도르시아 파마슈티컬스 리미티드 | (3s,7s,10r,13r)-13-벤질-20-플루오로-7-이소부틸-n-(2-(3-메톡시-1,2,4-옥사디아졸-5-일)에틸)-6,9-디메틸-1,5,8,11-테트라옥소-10-(2,2,2-트리플루오로에틸)-1,2,3,4,5,6,7,8,9,10,11,12,13,14-테트라데카히드로-[1]옥사[4,7,10,14]테트라아자시클로헵타데시노[16,17-f]퀴놀린-3-카르복사미드의결정질 형태 |
| WO2025076235A1 (en) | 2023-10-04 | 2025-04-10 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator |
| WO2025186214A1 (en) | 2024-03-05 | 2025-09-12 | Idorsia Pharmaceuticals Ltd | Macrocyclic cftr modulators |
Family Cites Families (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20020017295A1 (en) | 2000-07-07 | 2002-02-14 | Weers Jeffry G. | Phospholipid-based powders for inhalation |
| US6777400B2 (en) | 2000-08-05 | 2004-08-17 | Smithkline Beecham Corporation | Anti-inflammatory androstane derivative compositions |
| MXPA05003366A (es) | 2002-09-30 | 2005-10-05 | Univ California | Inhibidores de la proteina reguladora de conductancia transmembranal de la fibrosis quistica y usos de los mismos. |
| US20050113423A1 (en) | 2003-03-12 | 2005-05-26 | Vangoor Frederick F. | Modulators of ATP-binding cassette transporters |
| HUE031794T2 (en) | 2003-04-11 | 2017-08-28 | Ptc Therapeutics Inc | 1,2,4-oxadiol-benzoic acid compounds and their use for nonsense suppression and disease treatment |
| US7696244B2 (en) | 2003-05-16 | 2010-04-13 | The Regents Of The University Of California | Compounds having activity in increasing ion transport by mutant-CFTR and uses thereof |
| DE602004022819D1 (de) | 2003-06-06 | 2009-10-08 | Vertex Pharma | Von atp-bindende kassette transportern |
| CA2465565A1 (en) * | 2003-06-12 | 2004-12-12 | Warner-Lambert Company Llc | Pharmaceutical compositions of atorvastatin |
| CN1886393A (zh) | 2003-10-08 | 2006-12-27 | 沃泰克斯药物股份有限公司 | 含有环烷基或吡喃基基团的atp－结合弹夹转运蛋白的调控剂 |
| ATE437640T1 (de) | 2003-11-14 | 2009-08-15 | Vertex Pharma | Thiazole udn oxazole als modulatoren von atp- bindungs-kassetten-transportern |
| CA2561560A1 (en) | 2004-03-30 | 2005-10-13 | The Regents Of The University Of California | Hydrazide-containing cftr inhibitor compounds and uses thereof |
| CA2569402A1 (en) | 2004-06-04 | 2005-12-22 | The Regents Of The University Of California | Compounds having activity in increasing ion transport by mutant-cftr and uses thereof |
| PL2502911T3 (pl) | 2004-06-24 | 2017-09-29 | Vertex Pharma | Modulatory transporterów kasety wiążącej ATP |
| CA2583177A1 (en) | 2004-10-13 | 2006-04-27 | Ptc Therapeutics, Inc. | Compounds for nonsense suppression, and methods for their use |
| EP1865949B1 (en) | 2005-03-11 | 2012-11-14 | Vertex Pharmaceuticals Incorporated | Modulators of ATP-binding cassette transporters |
| CA2600869A1 (en) | 2005-03-18 | 2006-09-28 | The Regents Of The University Of California | Compounds having activity in correcting mutant-cftr processing and uses thereof |
| JP5800451B2 (ja) | 2005-04-08 | 2015-10-28 | ピーティーシー セラピューティクス，インコーポレーテッド | ナンセンス突然変異抑制治療用の、経口的に活性な１，２，４−オキサジアゾール組成物 |
| WO2006127588A2 (en) | 2005-05-24 | 2006-11-30 | Vertex Pharmaceuticals Incorporated | Modulators of atp-binding cassette transporters |
| KR20080064971A (ko) | 2005-10-06 | 2008-07-10 | 버텍스 파마슈티칼스 인코포레이티드 | Ａｔｐ-결합 카세트 전달체의 조절자 |
| DK1945632T3 (da) | 2005-11-08 | 2013-12-16 | Vertex Pharma | Heterocycliske modulatorer af ATP-bindende kassettetransportører |
| EP2332933A1 (en) | 2007-05-07 | 2011-06-15 | Novartis AG | Epithelial sodium channel (ENaC) inhibitors |
| CN101918366A (zh) * | 2007-09-14 | 2010-12-15 | 弗特克斯药品有限公司 | N-[2,4-双(1,1-二甲基乙基)-5-羟基苯基]-1,4-二氢-4-氧代喹啉-3-甲酰胺的固体形式 |
| KR20160040745A (ko) * | 2007-12-07 | 2016-04-14 | 버텍스 파마슈티칼스 인코포레이티드 | 3-(6-(1-(2,2-디플루오로벤조[ｄ][1,3]디옥솔-5-일)사이클로프로판카복스아미도)-3-메틸피리딘-2-일)벤조산의 고체 형태 |
| AR069637A1 (es) | 2007-12-10 | 2010-02-10 | Novartis Ag | Derivados de pirazinas |
| BRPI0915018A2 (pt) | 2008-06-10 | 2015-10-27 | Novartis Ag | compostos orgânicos |
| NZ591535A (en) * | 2008-08-13 | 2012-12-21 | Vertex Pharma | Pharmaceutcial composition comprising a solid dispersion of N-[2,4-Bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide |
| US20100074949A1 (en) | 2008-08-13 | 2010-03-25 | William Rowe | Pharmaceutical composition and administration thereof |
| AR073709A1 (es) | 2008-09-29 | 2010-11-24 | Vertex Pharma | Unidades de dosis de acido 3-(6-(1-(2,2-difluorobenzeno (d) (1,3) dioxol-5-il) ciclopropancarboxamido)-3-metilpiridin-2-il) benzoico |
| KR20120050928A (ko) * | 2009-06-02 | 2012-05-21 | 니칸 파마수티컬스, 엘엘씨 | 질병 치료용의 사람 포르밀 펩타이드 수용체의 길항제 |
| JP2011034380A (ja) * | 2009-08-03 | 2011-02-17 | Nitto Denko Corp | タッチパネルおよびタッチパネル付表示装置 |
| WO2011028740A1 (en) | 2009-09-03 | 2011-03-10 | Glaxo Group Limited | ENaC BLOCKERS |
| WO2011079087A1 (en) | 2009-12-23 | 2011-06-30 | Glaxo Group Limited | Enac blockers |
| US8247436B2 (en) | 2010-03-19 | 2012-08-21 | Novartis Ag | Pyridine and pyrazine derivative for the treatment of CF |
| NZ602838A (en) * | 2010-04-07 | 2015-06-26 | Vertex Pharma | Pharmaceutical compositions of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid and administration thereof |
| CA2796642A1 (en) * | 2010-04-22 | 2011-10-27 | Vertex Pharmaceuticals Incorporated | Pharmaceutical compositions and administrations thereof |
| US8372845B2 (en) | 2010-09-17 | 2013-02-12 | Novartis Ag | Pyrazine derivatives as enac blockers |
| US10105356B2 (en) * | 2011-01-31 | 2018-10-23 | Avalyn Pharma Inc. | Aerosol pirfenidone and pyridone analog compounds and uses thereof |
| US9968607B2 (en) | 2011-04-25 | 2018-05-15 | Hetero Research Foundation | Pharmaceutical compositions of raltegravir, methods of preparation and methods of use therof |
| PT2806859T (pt) * | 2012-01-25 | 2019-09-04 | Vertex Pharma | Formulações de ácido 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-il)ciclopropanocarboxamido)-3-metilpiridin-2-il)benzoico |
| EP4556008A3 (en) * | 2012-11-02 | 2025-08-27 | Vertex Pharmaceuticals Incorporated | Pharmaceutical compositions for the treatment of cftr mediated diseases |
| WO2015073231A1 (en) * | 2013-11-12 | 2015-05-21 | Vertex Pharmaceuticals Incorporated | Process of preparing pharmaceutical compositions for the treatment of cftr mediated diseases |
-
2013
- 2013-11-01 EP EP24223819.4A patent/EP4556008A3/en active Pending
- 2013-11-01 PT PT13792149T patent/PT2914248T/pt unknown
- 2013-11-01 FI FIEP13792149.0T patent/FI2914248T4/fi active
- 2013-11-01 UA UAA201505319A patent/UA117464C2/uk unknown
- 2013-11-01 EP EP18192504.1A patent/EP3470063B1/en active Active
- 2013-11-01 TW TW102139864A patent/TW201422253A/zh unknown
- 2013-11-01 DK DK13792149.0T patent/DK2914248T4/da active
- 2013-11-01 TW TW107117580A patent/TWI736768B/zh active
- 2013-11-01 AU AU2013337730A patent/AU2013337730B2/en active Active
- 2013-11-01 US US14/069,571 patent/US20140163068A1/en not_active Abandoned
- 2013-11-01 SI SI201332096T patent/SI3470063T1/sl unknown
- 2013-11-01 SM SM20180590T patent/SMT201800590T1/it unknown
- 2013-11-01 PT PT181925041T patent/PT3470063T/pt unknown
- 2013-11-01 RS RS20181318A patent/RS57831B2/sr unknown
- 2013-11-01 WO PCT/US2013/067952 patent/WO2014071122A1/en not_active Ceased
- 2013-11-01 FI FIEP18192504.1T patent/FI3470063T3/fi active
- 2013-11-01 UA UAA201803746A patent/UA123631C2/uk unknown
- 2013-11-01 KR KR1020157014464A patent/KR102396897B1/ko active Active
- 2013-11-01 HR HRP20181740TT patent/HRP20181740T4/hr unknown
- 2013-11-01 NZ NZ708474A patent/NZ708474A/en unknown
- 2013-11-01 PL PL18192504.1T patent/PL3470063T3/pl unknown
- 2013-11-01 SG SG10201913581UA patent/SG10201913581UA/en unknown
- 2013-11-01 MX MX2015005559A patent/MX368353B/es active IP Right Grant
- 2013-11-01 IL IL283276A patent/IL283276B2/en unknown
- 2013-11-01 TR TR2018/15218T patent/TR201815218T4/tr unknown
- 2013-11-01 DK DK18192504.1T patent/DK3470063T3/da active
- 2013-11-01 NZ NZ745659A patent/NZ745659A/en unknown
- 2013-11-01 LT LTEP18192504.1T patent/LT3470063T/lt unknown
- 2013-11-01 HU HUE18192504A patent/HUE070382T2/hu unknown
- 2013-11-01 HU HUE13792149A patent/HUE039864T2/hu unknown
- 2013-11-01 ES ES18192504T patent/ES3009747T3/es active Active
- 2013-11-01 RS RS20250226A patent/RS66596B1/sr unknown
- 2013-11-01 BR BR112015009913-0A patent/BR112015009913B1/pt active IP Right Grant
- 2013-11-01 EP EP13792149.0A patent/EP2914248B2/en active Active
- 2013-11-01 CN CN202010527346.2A patent/CN111671751A/zh active Pending
- 2013-11-01 CA CA2890106A patent/CA2890106C/en active Active
- 2013-11-01 CN CN201380066317.9A patent/CN104869982A/zh active Pending
- 2013-11-01 SM SM20250078T patent/SMT202500078T1/it unknown
- 2013-11-01 ES ES13792149T patent/ES2694290T5/es active Active
- 2013-11-01 SG SG11201503365YA patent/SG11201503365YA/en unknown
- 2013-11-01 LT LTEP13792149.0T patent/LT2914248T/lt unknown
- 2013-11-01 SI SI201331163T patent/SI2914248T2/sl unknown
- 2013-11-01 JP JP2015540796A patent/JP6302923B2/ja active Active
- 2013-11-01 PL PL13792149.0T patent/PL2914248T5/pl unknown
- 2013-11-01 HR HRP20250100TT patent/HRP20250100T1/hr unknown
- 2013-11-01 SG SG10201703452PA patent/SG10201703452PA/en unknown
- 2013-11-04 AR ARP130104018A patent/AR093340A1/es not_active Application Discontinuation
-
2015
- 2015-04-30 IL IL238551A patent/IL238551B/en active IP Right Grant
- 2015-04-30 CL CL2015001148A patent/CL2015001148A1/es unknown
- 2015-04-30 MX MX2019011662A patent/MX2019011662A/es unknown
-
2016
- 2016-05-11 US US15/152,092 patent/US20160324846A1/en not_active Abandoned
-
2018
- 2018-03-05 JP JP2018038741A patent/JP2018090626A/ja not_active Withdrawn
- 2018-09-14 AU AU2018229528A patent/AU2018229528A1/en not_active Abandoned
- 2018-11-30 CY CY20181101277T patent/CY1121070T1/el unknown
-
2019
- 2019-05-07 JP JP2019087813A patent/JP7003085B2/ja active Active
- 2019-12-20 US US16/722,290 patent/US20200338063A1/en not_active Abandoned
-
2020
- 2020-06-17 AU AU2020204037A patent/AU2020204037B2/en active Active
-
2021
- 2021-12-28 JP JP2021214209A patent/JP2022034069A/ja active Pending
-
2022
- 2022-12-30 US US18/091,472 patent/US20230364073A1/en active Pending
-
2024
- 2024-01-16 AU AU2024200273A patent/AU2024200273A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015535289A5 (enExample) | ||
| CN1633281A (zh) | 口内崩解的伐地考昔组合物 | |
| CA2601955A1 (en) | Pharmaceutical composition comprising an omega-carboxyaryl substituted diphenyl urea for the treatment of cancer | |
| KR20150001718A (ko) | 경구용 의약 조성물 | |
| CN101679390A (zh) | 奥美沙坦酯的粉碎结晶 | |
| TWI418370B (zh) | 溶出安定性製劑 | |
| US20100152173A1 (en) | Tablet Having Improved Stability With At Least Two Actives | |
| JP6160263B2 (ja) | ロキソプロフェン含有医薬組成物 | |
| JP6117591B2 (ja) | モサプリドと制酸剤とを含有する医薬組成物 | |
| AU2011276450A1 (en) | Pharmaceutical compositions containing vanoxerine | |
| JP2017520619A (ja) | セリチニブ製剤 | |
| WO2019124358A1 (ja) | 粒子径制御によるプレガバリンの化学的安定性の改善方法 | |
| KR20110063684A (ko) | 알리스키렌을 포함하는 생약 제형 및 용융 압출 과립화에 의한 그의 제조 방법 | |
| JP5873394B2 (ja) | タンニン酸ベルベリン粒子及びその製造方法、錠剤 | |
| CN1303284A (zh) | 8－氯－6,11－二氢－11－(4－亚哌啶基)－5H－苯并[5,6]环庚三烯并[1,2－b]吡啶口服组合物 | |
| CN103764126A (zh) | 具有高决奈达隆含量的药物组合物和固体盖伦形式及它们的制备方法 | |
| WO2024086712A2 (en) | Solid pharmaceutical tablet | |
| JP7627568B2 (ja) | オセルタミビルを含む錠剤及びその製造方法 | |
| JP6439503B2 (ja) | 固形製剤 | |
| CN104994842B (zh) | 高剂量柠檬酸钾蜡基质缓释片剂 | |
| JP5680607B2 (ja) | 安定固形製剤及びその製造法 | |
| JP7109255B2 (ja) | 粉砕物の製造方法及び錠剤の製造方法 | |
| CN103877064B (zh) | 一种非诺贝特胶囊剂及其制备工艺 | |
| JP6199922B2 (ja) | 化学的な安定性が向上したイルベサルタン含有錠剤 | |
| CA3143829C (en) | Pretomanid compositions |